Tech Transfer Roundup: Mustang, Juno Advance Efforts With Immuno-Oncology
Executive Summary
While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.
You may also be interested in...
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.
Mustang Leads Fortress's CAR-T Ambitions Of Monstrous Proportions
Emerging Company Profile: The two-year-old company combines the Fortress Biotech model with City of Hope's broad expertise in CAR-T technology, plus leadership from a pioneer in the space.